124 related articles for article (PubMed ID: 11401142)
1. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
Schmidt U; Han RO; DiSalvo TG; Guerrero JL; Gold HK; Zapol WM; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2001 Jun; 37(7):1981-8. PubMed ID: 11401142
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
[TBL] [Abstract][Full Text] [Related]
3. Inhaled nitric oxide increases coronary artery patency after thrombolysis.
Adrie C; Bloch KD; Moreno PR; Hurford WE; Guerrero JL; Holt R; Zapol WM; Gold HK; Semigran MJ
Circulation; 1996 Oct; 94(8):1919-26. PubMed ID: 8873669
[TBL] [Abstract][Full Text] [Related]
4. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome.
Adrie C; Holzmann A; Hirani WM; Zapol WM; Hurford WE
Anesthesiology; 2000 Aug; 93(2):422-30. PubMed ID: 10910492
[TBL] [Abstract][Full Text] [Related]
6. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
8. Site-specific effect of guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs.
Steinhorn RH; Gordon JB; Tod ML
Crit Care Med; 2000 Feb; 28(2):490-5. PubMed ID: 10708189
[TBL] [Abstract][Full Text] [Related]
9. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
Ivy DD; Kinsella JP; Ziegler JW; Abman SH
J Thorac Cardiovasc Surg; 1998 Apr; 115(4):875-82. PubMed ID: 9576224
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.
Nagamine J; Hill LL; Pearl RG
Crit Care Med; 2000 Jul; 28(7):2420-4. PubMed ID: 10921573
[TBL] [Abstract][Full Text] [Related]
11. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
Hsieh CP; Sakai K; Bruns GC; Dage RC
J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754
[TBL] [Abstract][Full Text] [Related]
12. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
Ziegler JW; Ivy DD; Wiggins JW; Kinsella JP; Clarke WR; Abman SH
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1388-95. PubMed ID: 9817684
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
Kitzen JM; McCallum JD; Harvey C; Morin ME
J Cardiovasc Pharmacol; 1991 Dec; 18(6):777-90. PubMed ID: 1725888
[TBL] [Abstract][Full Text] [Related]
14. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients.
Lepore JJ; Dec GW; Zapol WM; Bloch KD; Semigran MJ
J Heart Lung Transplant; 2005 Nov; 24(11):1950-6. PubMed ID: 16297803
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
Rübsamen K; Hornberger W; Kirchengast M
Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
[TBL] [Abstract][Full Text] [Related]
16. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
17. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models.
Roux SP; Sakariassen KS; Turitto VT; Baumgartner HR
Arterioscler Thromb; 1991; 11(5):1182-91. PubMed ID: 1911705
[TBL] [Abstract][Full Text] [Related]
18. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
Foubert L; De Wolf D; Mareels K; Van Belleghem Y; Reyntjens K; Mortier E; Van Nooten G
Pediatr Res; 2002 Nov; 52(5):730-6. PubMed ID: 12409521
[TBL] [Abstract][Full Text] [Related]
19. Selective pulmonary vasodilation induced by aerosolized zaprinast.
Ichinose F; Adrie C; Hurford WE; Bloch KD; Zapol WM
Anesthesiology; 1998 Feb; 88(2):410-6. PubMed ID: 9477062
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
Dukarm RC; Morin FC; Russell JA; Steinhorn RH
Pediatr Res; 1998 Dec; 44(6):831-7. PubMed ID: 9853914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
